When should we order an ACR (Albumin-to-Creatinine Ratio) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When to Order Albumin-to-Creatinine Ratio (ACR) Testing

The ACR test should be ordered annually in all adults with type 2 diabetes regardless of treatment duration, and in those with type 1 diabetes with duration of ≥5 years, using a morning spot urine sample. 1

Primary Indications for ACR Testing

Diabetes Screening

  • Type 1 Diabetes: Begin screening 5 years after diagnosis 1
  • Type 2 Diabetes: Begin screening at diagnosis 1
  • Frequency: Annual screening for all diabetic patients with normal results 1
  • More Frequent Testing: Every 6 months if:
    • eGFR <60 mL/min/1.73 m²
    • Previous ACR >30 mg/g creatinine
    • Hypertension present 1

High-Risk Populations

  • Patients with hypertension
  • Family history of kidney disease
  • History of cardiovascular disease
  • Obesity
  • Smoking history 2

Confirming Abnormal Results

  • An elevated ACR should be confirmed with 2 additional tests over the next 3-6 months 1
  • First-void morning urine samples are preferred for confirmation testing to reduce variability 1
  • Rule out transient causes of elevated ACR before confirming diagnosis:
    • Exercise
    • Urinary tract infection
    • Marked hyperglycemia
    • Marked hypertension
    • Congestive heart failure
    • Pyuria
    • Hematuria 2

Interpreting ACR Results

Classification of Albuminuria

Category ACR Range (mg/g creatinine)
Normal to mildly increased <30
Moderately increased (microalbuminuria) 30-299
Severely increased (macroalbuminuria) ≥300
[1]

Clinical Significance

  • ACR ≥30 mg/g indicates increased risk for CKD progression and cardiovascular events 2
  • ACR is superior to urine dipstick testing for detecting albuminuria:
    • Dipstick testing has poor sensitivity (43.6%) and high false-discovery rates for detecting ACR ≥30 mg/g 3
    • ACR provides better risk stratification for CKD progression 3

Monitoring Response to Treatment

  • After initiating treatment (ACE inhibitors/ARBs), monitor ACR every 3-6 months 2
  • A >30% sustained reduction in albuminuria is considered a surrogate marker of slowed kidney disease progression 1
  • Goal: Reduce ACR by at least 30-50% and ideally achieve ACR <30 mg/g 1

Practical Considerations

  • Sample Collection: First-void morning urine sample is preferred; random spot urine is acceptable when first-void is not practical 4
  • Point-of-Care Testing: While convenient, has lower sensitivity (83.2%) and positive predictive value (51.2%) compared to laboratory testing 5
  • Correlation with Total Protein: ACR correlates well with protein-to-creatinine ratio (PCR), but correlation is weaker in patients with low protein excretion or low urinary creatinine concentration 6

When to Refer to Nephrology

  • Uncertain etiology of kidney disease
  • Presence of hematuria with albuminuria
  • eGFR <60 mL/min/1.73m² with ACR >30 mg/g
  • Rapidly progressing kidney disease
  • Urgent referral if eGFR <30 mL/min/1.73m² 2

Common Pitfalls to Avoid

  • Relying solely on dipstick testing: Dipstick tests have poor sensitivity for detecting microalbuminuria compared to ACR 3
  • Not confirming abnormal results: Single elevated ACR may be transient; confirm with 2 additional tests 1
  • Ignoring urinary creatinine levels: Low urinary creatinine (<60 mg/dL) may affect the reliability of ACR results 6
  • Not considering transient causes: Exercise, infection, and acute hyperglycemia can temporarily increase albumin excretion 2

ACR testing is a critical component of kidney disease screening and management, particularly in diabetic patients, and should be incorporated into routine care to identify early kidney damage and guide treatment decisions.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.